G1 THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
G1 THERAPEUTICS INC. - More news...
G1 THERAPEUTICS INC. - More news...
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
- G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
- Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
- G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
- G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
- G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Participate in Two August Investor Conferences
- New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
- New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer